Phase 2 Study of Sacituzumab Govitecan for Adults With Previously Treated Diffuse Pleural Mesothelioma

What this Trial Is About

This research aims to evaluate sacituzumab govitecan in people with mesothelioma, specifically those with diffuse pleural mesothelioma who have previously received treatment. The study is a Phase 2 clinical trial sponsored by Memorial Sloan Kettering Cancer Center, focusing on patients whose disease has not responded to earlier therapies. Participants must have measurable disease and meet other health criteria to join the study. Participants will receive sacituzumab govitecan until their disease worsens, they experience severe side effects, or the study doctor or participant decides to stop treatment. Imaging scans will be done after the first two treatment cycles and then every three cycles to monitor disease progression. Biopsies will be taken at screening, before the third treatment cycle, and optionally at the end of treatment if it is safe and agreed upon. Throughout the study, patients will be closely monitored for treatment response and side effects. Researchers will assess overall response rate over two years, including toxicity and efficacy data. Participants who leave before the third cycle assessment will be monitored for side effects only. The study includes regular scans, biopsies, and health evaluations to track progress and safety during treatment and follow-up.

A Study of Sacituzumab Govitecan in People With Mesothelioma